Owlstone Medical advancing against cancer

Published on 09 May 17, under Press mentions

Owlstone Medical has been featured in Pharmaphorum's "Deep Dive Oncology" magazine. The article lists 5 companies leading the next generation of innovation in the cancer space, and describes our Breath Biopsy® platform, including our lung cancer collaboration with the NHS through the LuCID clinical trial. 

READ THE ARTICLE ONLINE

Five tech companies advancing against cancer

Marco Ricci - May 2017

Excerpt from the article:

“The advantage to VOCs is that they can be picked up earlier than signatures searched for in liquid biopsies, meaning cancer can be diagnosed earlier and treated more effectively.”

Media contact

For more information please contact:
Sarah Jeffery, Zyme Communications
sarah.jeffery@zymecommunications.com
+44 (0)7771 730 919

VOC biomarker discovery and validation research services with our world class team and facilities

View our services